MX2016009217A - Inmunoterapia basada en liposomas. - Google Patents

Inmunoterapia basada en liposomas.

Info

Publication number
MX2016009217A
MX2016009217A MX2016009217A MX2016009217A MX2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A
Authority
MX
Mexico
Prior art keywords
liposome
pharmaceutical
veterinary compositions
provides
defined above
Prior art date
Application number
MX2016009217A
Other languages
English (en)
Inventor
Maspoch Comamala Daniel
María Cano Sarabia Antonia
VIVES PI Marta
PUJOL AUTONELL Irma
Verdaguer Autonell Juan
Original Assignee
Fundació Inst D'investigació En Ciències De La Salut Germans Trias I Pujol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Inst D'investigació En Ciències De La Salut Germans Trias I Pujol filed Critical Fundació Inst D'investigació En Ciències De La Salut Germans Trias I Pujol
Publication of MX2016009217A publication Critical patent/MX2016009217A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un liposoma que encapsula un autoantígeno, en el que el liposoma tiene un tamaño comprendido entre 500 y 15000 nm y la membrana del liposoma comprende fosfatidilserina (PS) en una cantidad comprendida entre el 10 y el 40% en peso con respecto a la composición liposómica total de membrana. También se proporcionan composiciones farmacéuticas o veterinarias que comprenden una cantidad terapéuticamente eficaz de dicho liposoma. Además, la invención proporciona liposomas y composiciones farmacéuticas o veterinarias como se han definido anteriormente para uso como un medicamento, particularmente para el tratamiento de enfermedades autoinmunes. Finalmente la presente invención proporciona liposoma y composiciones farmacéuticas o veterinarias como se ha definido anteriormente para uso en la restauración de autotolerancia en un paciente que padece una enfermdad autoinmune.
MX2016009217A 2014-01-17 2015-01-16 Inmunoterapia basada en liposomas. MX2016009217A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14151629 2014-01-17
PCT/EP2015/050747 WO2015107140A1 (en) 2014-01-17 2015-01-16 Liposome-based immunotherapy

Publications (1)

Publication Number Publication Date
MX2016009217A true MX2016009217A (es) 2017-05-12

Family

ID=49949574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009217A MX2016009217A (es) 2014-01-17 2015-01-16 Inmunoterapia basada en liposomas.

Country Status (12)

Country Link
US (1) US12048765B2 (es)
EP (1) EP3094345B1 (es)
JP (2) JP6546195B2 (es)
CN (1) CN106061502B (es)
AU (1) AU2015206016B2 (es)
BR (1) BR112016016356B1 (es)
CA (1) CA2939435C (es)
ES (1) ES2672247T3 (es)
MX (1) MX2016009217A (es)
PL (1) PL3094345T3 (es)
TR (1) TR201807778T4 (es)
WO (1) WO2015107140A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094345B1 (en) * 2014-01-17 2018-03-14 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Liposome-based immunotherapy
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
CN109963570A (zh) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
US11315437B2 (en) * 2017-02-24 2022-04-26 Rene Ebner-Todd Nutrition management and kitchen appliance
EP4061408A4 (en) * 2019-11-22 2024-04-10 The Research Foundation for the State University of New York COMPOSITIONS AND METHODS FOR USE IN TYPE 1 DIABETES
WO2024110516A1 (en) 2022-11-23 2024-05-30 Ahead Therapeutics, S.L. Tolerogenic composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
ES2187812T3 (es) * 1996-09-13 2003-06-16 Lipoxen Technologies Ltd Composicion de liposomas.
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
CN1997395B (zh) * 2004-06-11 2012-08-29 独立行政法人理化学研究所 含有包含在脂质体中的调节性细胞配体的药物
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
EP1909758A1 (en) * 2005-08-02 2008-04-16 I.D.M. Immuno-Designed Molecules Process for the preparation of liposomal formulations
MX350501B (es) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
ES2650236T3 (es) * 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
CN101502649B (zh) * 2008-06-23 2011-11-30 深圳职业技术学院 一种脂质体流感疫苗
WO2011005850A1 (en) * 2009-07-07 2011-01-13 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
EP2907504B1 (en) * 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
MX2013012593A (es) * 2011-04-29 2014-08-21 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
WO2013184976A2 (en) * 2012-06-06 2013-12-12 Northwestern University Compositions and methods for antigen-specific tolerance
EP3094345B1 (en) * 2014-01-17 2018-03-14 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Liposome-based immunotherapy

Also Published As

Publication number Publication date
CA2939435C (en) 2023-09-19
PL3094345T3 (pl) 2018-11-30
JP2019196363A (ja) 2019-11-14
US12048765B2 (en) 2024-07-30
ES2672247T3 (es) 2018-06-13
JP6546195B2 (ja) 2019-07-17
US20160338953A1 (en) 2016-11-24
TR201807778T4 (tr) 2018-06-21
EP3094345B1 (en) 2018-03-14
JP2017507171A (ja) 2017-03-16
CN106061502B (zh) 2021-04-13
BR112016016356A2 (pt) 2017-10-03
WO2015107140A1 (en) 2015-07-23
EP3094345A1 (en) 2016-11-23
AU2015206016B2 (en) 2020-07-23
CA2939435A1 (en) 2015-07-23
CN106061502A (zh) 2016-10-26
AU2015206016A1 (en) 2016-08-25
BR112016016356B1 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX2016009217A (es) Inmunoterapia basada en liposomas.
AU2017265937A1 (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
IN2015DN00376A (es)
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
EA201492047A1 (ru) Пролипосомальные композиции тестостерона
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
WO2015033302A3 (en) Fulvestrant compositions
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions

Legal Events

Date Code Title Description
FG Grant or registration